Scientists at the University of Birmingham have developed a type of eye drop which could potentially revolutionise the treatment of one of the leading causes of blindness in the UK.
The results of the collaborative research, published today in Investigative Opthamology and Visual Science, could spell the end of painful injections directly into the eye to treat the increasingly common eye disorder known as age-related macular degeneration (AMD).
AMD affects more than 600,000 people in the UK and predictions suggest this figure could rise sharply in future because of an ageing population.
A painless condition which causes people to gradually lose their central vision, usually in both eyes, AMD is currently treated by repeated injections into the eye on a monthly basis over at least three years.
This is a problem because, apart from being an unpleasant procedure for patients to undergo, the injections can cause tearing and infections inside the eye and an increased risk of blindness.
Now scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Inflammation and Ageing, have invented a method of delivering the injected drug as an eye drop instead, and their laboratory research has obtained the same outcomes as the injected drug.
The drop uses a cell-penetrating peptide (CPP) to deliver the drug to the relevant part of the eye within minutes.
Dr de Cogan said: “The CPP-drug has the potential to have a significant impact on the treatment of AMD by revolutionising drug-delivery options.
“Efficacious self-administered drug application by eye drop would lead to a significant reduction in adverse outcomes and health care costs compared with current treatments.
“The CPP-plus drug complex also has potential application to other chronic ocular diseases that require drug delivery to the posterior chamber of the eye.
“We believe this is going to be very important in terms of empowering of patients and reducing the cost of treatment to the NHS.”
The Latest on: Age-related macular degeneration
- Pixium Vision wins French approval for Prima sub-retinal implant study on October 19, 2017 at 7:24 am
Pixium Vision (EPA:PIX) said today it won approval from France’s regulatory agency to launch a feasibility clinical study of its next-gen Prima sub-retinal implant in patients with advanced dry age-related macular degeneration. The Prima system is a ... […]
- Gemini Therapeutics closes $42.5M Series A for dry age-related macular degeneration therapy on October 19, 2017 at 1:20 am
Gemini Therapeutics has closed a Series A round to advance its precision medicine therapy for dry age-related macular degeneration. The Cambridge, Massachusetts company zeroes in on genetic causes of the condition. James McLaughlin, Gemini Therapeutics ... […]
- Lutein & Zeaxanthin Supplementation for Macular Degeneration Could Lead to Significant Health Care Savings on October 18, 2017 at 11:00 am
MONTREAL, QUEBEC, CANADA, October 18, 2017 /EINPresswire.com/ -- Age-related macular degeneration (AMD) is the number one cause of vision loss in adults over 50 in North America. It is a progressive disease that causes damage to the retina and impairs the ... […]
- “Nutrition is Key to Beating Macular Degeneration,” Says Author on October 18, 2017 at 8:48 am
This condition, also known as age-related macular degeneration (ARMD), is a common eye disease and a leading cause of vision loss among people age 50 and above. In the Empowering Family Caregivers show on Blog Talk Radio, the author confirms ... […]
- Automated drusen detection in dry age-related macular degeneration by multiple-depth, en face optical coherence tomography on October 17, 2017 at 7:57 am
D. C. Neely, K. J. Bray, C. E. Huisingh, M. E. Clark, G. McGwin, and C. Owsley, “Prevalence of Undiagnosed Age-Related Macular Degeneration in Primary Eye Care,” JAMA Ophthalmol. 135(6), 570–575 (2017). [PubMed] D. Pascolini and S. P. Mariotti ... […]
via Google News and Bing News